IL19 and psoriasis: Following these results, we measured IL-19 in genital psoriasis patients enrolled in a phase 3b ixekizumab trial at baseline and after 2, 4, and 12 weeks of treatment with placebo or ixekizumab (160 mg loading dose followed by 80 mg Q2W).